Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:FEMY NASDAQ:IMVT NASDAQ:SLNO NYSE:SOLV On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeFEMYFemasys$0.92-1.1%$0.95$0.69▼$1.80$29.99M-2.56264,649 shs27,882 shsIMVTImmunovant$17.69+1.1%$15.63$12.72▼$34.47$3.00B0.631.22 million shs247,834 shsSLNOSoleno Therapeutics$84.63+1.2%$79.16$41.50▼$90.32$4.26B-2.63838,319 shs543,509 shsSOLVSolventum$72.50-1.6%$73.84$49.64▼$85.92$12.54B0.551.09 million shs114,992 shs7 Stocks to Buy And Hold ForeverEnter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceFEMYFemasys-0.79%+1.36%+4.86%-13.66%-16.74%IMVTImmunovant-5.92%+3.55%+11.69%+17.86%-42.67%SLNOSoleno Therapeutics+1.00%-1.96%+5.61%+19.53%+66.48%SOLVSolventum-0.53%-1.82%+0.10%+12.16%+52.81%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationFEMYFemasys2.8639 of 5 stars3.53.00.00.02.22.50.6IMVTImmunovant1.3526 of 5 stars3.40.00.00.02.21.70.0SLNOSoleno Therapeutics4.5825 of 5 stars4.51.00.04.62.72.50.6SOLVSolventum0.7261 of 5 stars2.12.00.00.02.70.00.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceFEMYFemasys 3.00Buy$8.67839.99% UpsideIMVTImmunovant 2.82Moderate Buy$36.30105.22% UpsideSLNOSoleno Therapeutics 3.09Buy$108.7028.45% UpsideSOLVSolventum 2.27Hold$84.3816.38% UpsideCurrent Analyst Ratings BreakdownLatest SLNO, FEMY, IMVT, and SOLV Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/15/2025SOLVSolventumMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeEqual Weight ➝ Overweight$80.00 ➝ $103.007/11/2025SLNOSoleno TherapeuticsRobert W. BairdSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetOutperform ➝ Outperform$105.00 ➝ $121.007/10/2025IMVTImmunovantThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold$18.007/1/2025SOLVSolventumArgusSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold ➝ Buy$90.006/25/2025FEMYFemasysHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$12.006/23/2025SLNOSoleno TherapeuticsCowenSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy6/23/2025SLNOSoleno TherapeuticsTD CowenSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$110.006/11/2025FEMYFemasysHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$12.006/6/2025SOLVSolventumKeyCorpSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageSector Weight5/19/2025SOLVSolventumPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeNeutral ➝ Overweight$78.00 ➝ $87.005/13/2025FEMYFemasysJones TradingSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$10.00 ➝ $6.00(Data available from 7/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookFEMYFemasys$1.63M18.40N/AN/A$0.10 per share9.22IMVTImmunovantN/AN/AN/AN/A$4.16 per shareN/ASLNOSoleno TherapeuticsN/AN/AN/AN/A$5.68 per shareN/ASOLVSolventum$8.31B1.51$9.73 per share7.45$17.13 per share4.23Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateFEMYFemasys-$18.82M-$0.91N/AN/AN/A-1,242.06%-392.45%-137.15%8/14/2025 (Estimated)IMVTImmunovant-$413.84M-$2.74N/AN/AN/AN/A-80.60%-71.89%8/5/2025 (Estimated)SLNOSoleno Therapeutics-$175.85M-$4.62N/AN/AN/AN/A-77.52%-63.44%8/6/2025 (Estimated)SOLVSolventum$478M$2.1633.5713.211.904.55%31.01%6.53%8/4/2025 (Estimated)Latest SLNO, FEMY, IMVT, and SOLV EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/6/2025Q2 2025SLNOSoleno Therapeutics-$0.85N/AN/AN/A$3.91 millionN/A8/5/2025Q1 2026IMVTImmunovant-$0.69N/AN/AN/AN/AN/A5/29/2025Q4 2025IMVTImmunovant-$0.72-$0.64+$0.08-$0.64N/A$0.16 million5/8/2025Q1 2025FEMYFemasys-$0.17-$0.23-$0.06-$0.23$1.14 million$0.34 million5/8/2025Q1 2025SOLVSolventum$1.19$1.34+$0.15$0.78$2.02 billion$2.07 billion5/7/2025Q1 2025SLNOSoleno Therapeutics-$1.14-$0.95+$0.19-$0.95N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthFEMYFemasysN/AN/AN/AN/AN/AIMVTImmunovantN/AN/AN/AN/AN/ASLNOSoleno TherapeuticsN/AN/AN/AN/AN/ASOLVSolventumN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioFEMYFemasys0.020.930.54IMVTImmunovantN/A11.1611.16SLNOSoleno Therapeutics0.2119.6419.64SOLVSolventum2.401.190.85Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipFEMYFemasys65.27%IMVTImmunovant47.08%SLNOSoleno Therapeutics97.42%SOLVSolventumN/AInsider OwnershipCompanyInsider OwnershipFEMYFemasys11.54%IMVTImmunovant1.80%SLNOSoleno Therapeutics6.40%SOLVSolventum0.05%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableFEMYFemasys3032.53 million28.77 millionNot OptionableIMVTImmunovant120171.07 million167.99 millionOptionableSLNOSoleno Therapeutics3050.39 million47.17 millionOptionableSOLVSolventum22,000173.01 million172.93 millionOptionableSLNO, FEMY, IMVT, and SOLV HeadlinesRecent News About These CompaniesStratos Wealth Partners LTD. Has $324,000 Position in Solventum Corporation (NYSE:SOLV)July 16 at 3:46 AM | marketbeat.comMorgan Stanley Upgrades Solventum (SOLV)July 15 at 7:46 PM | msn.comSolventum (NYSE:SOLV) Upgraded by Morgan Stanley to "Overweight" RatingJuly 15 at 8:59 AM | marketbeat.comAdvanced Wound Care Market worth $19.32 billion by 2030 with 7.6% CAGR | MarketsandMarkets™July 15 at 8:17 AM | prnewswire.co.ukPMayar Capital Ltd. Purchases 56,700 Shares of Solventum Corporation (NYSE:SOLV)July 15 at 8:14 AM | marketbeat.comBank of New York Mellon Corp Cuts Position in Solventum Corporation (NYSE:SOLV)July 12, 2025 | marketbeat.comTandem Diabetes, Solventum, LeMaitre, UFP Technologies, and Artivion Stocks Trade Down, What You Need To KnowJuly 11, 2025 | msn.comSolventum Launches Two Dental Innovations in ThailandJuly 10, 2025 | msn.comSolventum Corp (SOLV) Upgraded to a ‘Buy’ at Argus ResearchJuly 9, 2025 | finance.yahoo.comSamson Rock Capital LLP Acquires New Position in Solventum Corporation (NYSE:SOLV)July 9, 2025 | marketbeat.comDiscussing the removal of dissolved gases from water with SolventumJuly 8, 2025 | watertechonline.comWTeacher Retirement System of Texas Invests $5.08 Million in Solventum Corporation (NYSE:SOLV)July 8, 2025 | marketbeat.comIs the Options Market Predicting a Spike in Solventum Stock?July 7, 2025 | zacks.comKeybank National Association OH Has $2.94 Million Stock Position in Solventum Corporation (NYSE:SOLV)July 5, 2025 | marketbeat.comSumitomo Mitsui DS Asset Management Company Ltd Raises Holdings in Solventum Corporation (NYSE:SOLV)July 5, 2025 | marketbeat.comNew York State Teachers Retirement System Trims Stock Position in Solventum Corporation (NYSE:SOLV)July 5, 2025 | marketbeat.comSolventum Corporation (NYSE:SOLV) Given Average Rating of "Hold" by AnalystsJuly 4, 2025 | marketbeat.comFirst Bank & Trust Purchases Shares of 3,667 Solventum Corporation (NYSE:SOLV)July 3, 2025 | marketbeat.comArgus Research Upgrades Solventum (SOLV)July 2, 2025 | msn.comSolventum (NYSE:SOLV) Raised to "Buy" at ArgusJuly 1, 2025 | marketbeat.comKBC Group NV Increases Position in Solventum Corporation (NYSE:SOLV)July 1, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeSLNO, FEMY, IMVT, and SOLV Company DescriptionsFemasys NASDAQ:FEMY$0.92 -0.01 (-1.13%) As of 11:52 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Femasys Inc., a biomedical company, develops therapeutic and diagnostic solutions to address unmet women healthcare needs worldwide. The company provides FemVue saline-air device, a contrast-generating product in the United States, Canada, Japan, and Hong Kong; FemCath, a cornual balloon catheter, a single intrauterine directional delivery product that allows for selective evaluation of an individual fallopian tube; and FemCerv, a biopsy device for endocervical curettage, which can be used to sample cervical cells and tissue circumferentially with sample containment within the device to minimize contamination. It also develops permanent birth control solutions, such as FemBloc and FemChec; FemaSeed, an artificial insemination solution; and FemEMB, a product candidate for endometrial sampling in support of uterine cancer detection testing. The company offers its products to reproductive endocrinologists for infertility products, obstetrics-gynecological physicians, related healthcare professionals, and women's healthcare provider organizations. Femasys Inc. was incorporated in 2004 and is headquartered in Suwanee, Georgia.Immunovant NASDAQ:IMVT$17.69 +0.20 (+1.13%) As of 12:06 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, and Graves diseases, as well as warm autoimmune hemolytic anemia. The company is headquartered in New York, New York. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd.Soleno Therapeutics NASDAQ:SLNO$84.62 +1.04 (+1.24%) As of 12:06 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet, which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is based in Redwood City, California.Solventum NYSE:SOLV$72.50 -1.18 (-1.60%) As of 12:06 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The Medsurg segment is a provider of solutions including advanced wound care, I.V. site management, sterilization assurance, temperature management, surgical supplies, stethoscopes, and medical electrodes. The Dental Solutions segment provides a comprehensive suite of dental and orthodontic products including brackets, aligners, restorative cements, and bonding agents. The Health Information Systems provides software solutions including computer-assisted, physician documentation, direct-to-bill and coding automation, classification methodologies, speech, recognition, and data visualization platforms. The Purification and Filtration segment provides purification and filtration technologies including filters, purifiers, cartridges, and membranes. The company was incorporated in 2023 and is based in Saint Paul, Minnesota. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Pelosi Makes Big Bet on Broadcom—Here’s Why It Matters 3 Analysts Set $600 Target Ahead of Microsoft Earnings JPMorgan Q2 Results Affirm Dividend, Buybacks, & Growth NVDA Greenlight: China H20 Sales Spark 50% Rally Potential Tesla: 2 Plays Ahead of Next Week's Earnings Report New Catalyst Sends Joby Stock to 52-Week Highs Palantir Gets Price Hike From Wedbush Amid High Valuation Delta Air Lines Stock Rallies on New Guidance—Can It Keep Going? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
